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Polymorphism in β-fibrinogen and Integrin beta-3 Genes and Risk of 
Recurrent Spontaneous Miscarriage in Gaza Strip 
Abstract 
Background:  
Recurrent pregnancy loss (RPL) is an important clinical and stressful problem that 
has been studied tremendously. RPL affects about 1-5% of women who conceive. RPL 
has been defined as three or more consecutive pregnancy losses before 24 weeks of 
gestation. Despite extensive researches to explain the causative effects of RPL, about 
50% of RPLs are still idiopathic. Common  polymorhisms of β –fibrinogen (-455 G>A) 
and Integrin beta-3 genes have been indicated as risk factors for RPL in certain 
populations.  
Objective:  
This study was designed in order to investigate the relation
 
between RPL and 
common polymorphisms in β -fibrinogen (-455 G>A) and Integrin beta-3 (L33P) genes 
among Palestinian women experiencing RPL in Gaza Strip. 
Methods:  
This study is an association study with a case-control design. Using molecular 
biological techniques, the β–fibrinogen (-455 G>A), and Integrin beta-3 (L33P) 
common polymorphisms were determined for 102 women who had at least three 
constitutive abortions and 97 controls without a previous history of abortion. 
Results:   
The β–fibrinogen 455A/A  polymorphism was present in 3.9% of the patients and in 4.1% 
of the controls (P= 0.9422). Similarly there was no significant difference detected in the 
distribution of the HPA-1 (b/b)  polymorphism which was detected in 2.0 %  of the patients and 
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in 2.1% of the controls (P= 0.9595). The frequency of β–fibrinogen – 455 A allele is 20.1% 
and the frequency of HPA-1b allele is 19% in the Palestinian population.  
Conclusion:  
Results of the present study revealed that there is no significant association between the 
β–fibrinogen (-455 G>A) or  Integrin beta-3 (L33P) common polymorphisms and the 
occurrence of first trimester RPL. This non-significant relation indicates that the 
investigated polymorphisms do not constitute a tangible risk factor for RPL in our 
population.  Future work should focus on association of other polymorphisms and genes 
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المتكرر في قطاع غزة.و حذوث االجهاض  3-عالقت التعذد الشكلي لجيني البيتافيبرينىجين و االنتجرين بيتا   
 الملخص
يعزجش االجهبع انًزكشس يشكهخ هبيخ و يجهذح و نقذ رًذ دساسزهب ثشكم كجيش. فقذاٌ انحًم انًزكشس  :مقذمت
% يٍ حبالد فقذاٌ انحًم 02% يٍ انُسبء انشاغجبد في اإلَجبة و يًضم االجهبع حىاني  5-1يظيت حىاني 
عششيٍ أسثعخ و قجم إرًبو ثفقذاٌ انحًم نضالس يشاد عهً انزىاني  يعشف اإلجهبع انًزكشسانًضجزخ سشيشيب. 
و عهً انشغى يٍ األثحبس انىاسعخ انُطبق  نششح اآلصبس  انًسججخ نفقذاٌ انحًم انًزكشس اال اٌ أسجىعب يٍ انحًم،
هًىسصبد يعزقذ أٌ نهب عالقخ طشاص انجيُي نان% يٍ حبالد اإلجهبع يب صانذ يجهىنخ انسجت. 52حىاني 
 . 3شيُىجيٍ و االَزجشيٍ ثيزب انجيزب فيج ثبإلجهبع انًزكشس ويٍ ضًُهب
(  L33P) 3( و االَزجشيٍ ثيزب  555G>Aانجيزب فيجشيُىجيٍ ) ًَبط انًخزهفخ نهجيٍاألثيٍ انعالقخ دساسخ  الهذف:
 وحذوس اإلجهبع انًزكشس في قطبع غضح.
ايشاح رى فقذ انجُيٍ فيهب نضالس يشاد يززبنيخ في  102نقذ رى فحض رهك االخزالفبد انجيُيخ في  الطرق المستخذمت:
ايشأح نى ركٍ رعبَي يٍ اإلجهبع انًزكشس ورى رنك ثبسزخذاو رقُيبد  97انضهش األول يٍ انحًم وقىسَذ ثـ 
 انجيىنىجيب انجضيئيخ انحذيضخ.
في انجيُخ ثيزب   A/Aوجىد عالقخ راد دالنخ إحظبئيخ ثيٍ انشكم  أظهشد َزبئج هزِ انذساسخ عذو  النتائج:
% يٍ حبالد اإلجهبع انًزكشس ثيًُب وجىدِ كبٌ 3.3في  نطشاصفيجشيُىجيٍ و حذوس اإلجهبع حيش وجذ هزا ا
 b/b طشاصحيش وجذ ان 3( . و كزنك ثبنُسجخ نهجيُخ اَزجشيٍ ثيزب P = 0.9422% )5.1في انعيُخ انضبثطخ ثُسجخ  
. يٍ خالل انذساسخ وجذ أٌ (P= 0.9595)عيُخ انضبثطخ % في ان0.1% في حبالد االجهبع و ثُسجخ 0.2ثُسجخ 
 b% وَسجخ وجىد االنيم 02.1انخبص ثجيٍ انجيزب فيجشيُىجيٍ  في انًجزًع انفهسطيُي هي  Aَسجخ وجىد االنيم 
 % .13هي  3انخبص ثبنجيُخ اَزجشيٍ ثيزب 
 L33P) 3( و االَزجشيٍ ثيزب  555G>Aانجيزب فيجشيُىجيٍ )َسزُزج يٍ هزا انجحش عذو وجىد عالقخ ثيٍ  الخالصت:
و حذوس اإلجهبع انًزكشس في انضهش األول يٍ انحًم، وثزنك فبٌ هزِ انطشص انجيُيخ الرشكم عبيم خطش ( 
يهًىط نالجهبع انًزكشس في قطبع غضح. ورىطي انذساسخ ثبجشاء اثحبس عهً انعالقخ ثيٍ اخزالفبد جيُيخ اخشي 
 في جيُبد نهب عالقخ ثبنزخضش واإلجهبع انًزكشس. 
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Chapter (1)                  Introduction 
1.1. Overview 
Normal pregnancy is associated with major changes in many aspects of homeostasis 
all contributing to maintain placental function during pregnancy and to prevent 
excessive bleeding in delivery (Prisco et al., 2005). 
Recurrent pregnancy loss (RPL), also known as recurrent miscarriage (RM), is 
defined as three or more consecutive pregnancy losses before the 24th week of gestation 
(WHO, 2009), however, two or more losses were also considered in some studies (Abu-
Asab et al., 2011). RPL is a devastating problem, particularly to Palestinian families 
who are fond of having large families (Sharif, 2012). 
Based on the incidence of sporadic pregnancy loss, the incidence of recurrent 
pregnancy loss should be approximately 1 in 300 pregnancies (Ford and Schust, 2009). 
However, epidemiologic studies have revealed that 9-13% of women in the 
reproductive age group experience one clinically recognized loss, 5% experience two or 
more losses, and 1 to 2% suffer three or more losses (Lavigne et al., 2005). 
RPL has many possible causes that can be categorized as genetic abnormalities, 
hormonal and metabolic disorders, uterine anatomic abnormalities, infectious causes, 
immune disorders and thrombophilic disorders (Sharif, 2012). Although several medical 
causes have been established, the cause(s) in up to 50% of RPL cases remains 
unexplained after standard gynecological, hormonal, and karyotypic investigations 
(Lavigne et al., 2005; Ford and Schust, 2009). 
Thrombophilia can be defined as a predisposition to form clots inappropriately. 
Thrombotic events are increasingly recognized as a significant source of mortality and 
morbidity (Khan and Dickerman, 2006). 
Both inherited and combined inherited / acquired thrombophilias are common, with 
more than 15% of the white population carrying an inherited thrombophilic mutation  
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 (Ford and Schust, 2009) and this constitutes one important mechanism for clotting in 
the placental vessels. 
The most common cause of acquired thrombophilia is antiphospholipid antibodies. 
Inherited thrombophilias can result from gene mutations and only the inherited and 
newly documented are more closely followed. Factors are further grouped based on its 
thrombophilic taxonomy into; inherited defects of coagulation (e.g., Factor V von 
Leiden, Factor II Prothrombin, Fibrinogen, Factor XIII), inherited defects of fibrinolysis 
(e.g., Plasminogen activator inhibitor-1(PAI-1)), inherited defects of enzymatic pathway 
in relation to development of venous thromboembolism (VTE) and inherited defects of 
platelets and thrombosis (Human Platelet Antigen-1(HPA) (also Known as Integrin 
beta-3), Methylene tetrahydrofolate reductase “MTHFR”) (Konecny, 2009). 
Inherited thrombophilias are associated with recurrent miscarriage. This association 
is manifested by total number of mutations rather than specific genes involved (Coulam 
et al.,2006). 
This study is designed to investigate the association between spontaneous recurrent 
pregnancy loss (RPL) and the common polymorphisms in β-fibrinogen (-455 G>A; 
"rs1800790") and Integrin beta-3 a/b (L33P; " rs5918") genes among Palestinian 
women residing in Gaza Strip. 
1.2. Problem 
Recurrent pregnancy loss (RPL) is an important clinical and stressful problem that 
has been studied tremendously but the causes and treatment have not been fully 
resolved. No unequivocal cause is currently available for more than half of the cases 
suffering from RPL (Makino et al.,2004).  
Since the cause of RPL can be identified in only 50% of cases, there are still many 
unresolved questions about the causes and treatment of RPL. Fortunately, the number of 
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publications on this topic have substantially increased over the past 10 years, reflecting 
a growing interest among clinicians and scientists in this problem (Ledingham et 
al.,2000). 
The effect of polymorphisms in β-fibrinogen(-455 G>A), and Integrin beta-3 a/b 
(L33P) genes on the risk of RPL in the Palestinian population has not been explored yet.  
1.3. Overall objective 
To investigate the association between recurrent pregnancy loss (RPL) and the 
common polymorphisms (-455G>A) in β-fibrinogen gene and (L33P) in Integrin beta-3 
a/b  gene. 
1.4. Specific Objectives 
 Investigate the association between -455G>A polymorphism in β-fibrinogen 
gene and RPL. 
 Investigate the association between a/b (L33P) polymorphism in Integrin beta-3 
gene and RPL 
 Determine the frequency of -455G>A and L33P in our population. 








Chapter (1)                  Introduction 
1.5. Significance of the study 
 Up to 50% of cases of recurrent pregnancy loss, defined as two or more 
spontaneous abortions, still remain unexplained after standard gynecological, 
hormonal, and karyotypic investigations. 
 The study will be done to determine the incidence of polymorphisms in β-
fibrinogen (-455G>A), and HPA-1 a/b (L33P) genes and to determine the 
possible association between those polymorphisms and RPL. 
 The study is the first to be done in Gaza Strip. 











Chapter (2)                    Literature Review 
2.1. Pregnancy and hemostatic changes 
The Practice Committee of the American Society for Reproductive Medicine 
(ASRM) defines pregnancy as a clinical pregnancy documented by ultrasonography or 
histopathologic examination (Kutteh and Odom, 2012). 
Pregnancy is considered to be a hypercoagulable state due to the physiological 
changes of pregnancy and with increased tendency for thrombus formation (Thornton 
and Douglas, 2009; Carbone and Rampersad, 2010; Hussein et al.,2010). 
Normal pregnancy is associated with changes in the coagulation and fibrinolytic 
system of Hemostasis. These include a decrease in platelet count, increases in a number 
of clotting factors, a decrease in anticoagulant factor, protein S, a significant fall in the 
activity of activated protein C and inhibition of fibrinolysis. These changes that result in 
a state of hypercoagulability are likely due to hormonal changes and increase the risk of 
thromboembolism (Prisco et al.,2005; Thornton and Douglas, 2009). A fine balance 
between coagulation and fibrinolysis is critical in early pregnancy (Su et al., 2013). 
The increase in clotting activity is greatest at the time of delivery with placental 
expulsion, releasing thromboplastic substances. These substances stimulate clot 
formation to stop maternal blood loss, these changes may be important for reducing 
intrapartum blood loss. 
Coagulation and fibrinolysis generally return to pre-pregnant levels 3-4 weeks 
postpartum (Prisco et al.,2005; Thornton and Douglas, 2009). The placenta is a unique 
organ with dual blood circulations: maternal blood flows in the intervillous space and 
decidual blood vessels while fetal blood flows inside placental villi. The hemostatic 
balance is very sensitive in the placenta. There is a continuous low level fibrin 
production in the placenta reflected in raised levels of plasma D-dimer (Morse, 2004; 
Kline et al., 2005). Fetal well-being depends critically on the supply and flow properties 
of the uteroplacental system (Bremme, 2003). 
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2.2. Pregnancy loss 
Pregnancy loss or miscarriage can be defined as loss of a pregnancy before 20 
gestational weeks (Kutteh and Odom, 2012). 
About 9-13% of women in the reproductive age group experience one clinically 
recognized loss, 5% experience two or more losses, and 1 to 2% suffer three or more 
losses. Up to 50% of cases of recurrent pregnancy loss, still remain unexplained after 
standard gynecological, hormonal, and karyotypic investigations (Lavigne et al., 2005). 
Only 30% of all conceptions result in a live birth (Ford and Schust, 2009). 
 
2.3. Recurrent pregnancy loss 
Recurrent pregnancy loss (RPL); also referred to as recurrent miscarriage (RM) or 
habitual abortion (Ford and Schust, 2009);  is the occurrence of repeated pregnancies 
that end in miscarriage of the fetus, usually before 20 weeks of gestation (WHO, 2009).  
Conventionally, recurrent pregnancy loss has been defined as three consecutive 
pregnancy losses at less than 24 weeks of gestation. However, the American Society of 
Reproductive Medicine (ASRM) redefined recurrent pregnancy loss as two or more 
failed clinical pregnancies as documented by ultrasonography or histopathologic 
examination (Allison and schust, 2009). 
RPL has been inconsistently defined. When defined as 3 consecutive pregnancy 
losses prior to 20 weeks from the last menstrual period, it affects approximately 1% to 
2% of women (Stirrat, 1990; Ford and Schust, 2009).  
Clinical studies indicate that the risk of another miscarriage after 3 consecutive 
pregnancy losses is 30-45%. Furthermore, without any workup or treatment, the chance 
of a successful live birth in a couple with a history of RPL and no previous live birth is  
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55-60%. If the couple has a history of RPL and has had at least one previous normal 
pregnancy, the chance of a subsequent live birth is 70%. These percentages are based on 
studies of younger women, and it is important to keep in mind that the miscarriage rate 
increases with age (Evans, 2012). 
The ASRM recommends that couples who have 2 or more consecutive spontaneous 
miscarriages warrant an evaluation to identify any factor that may be associated with 
their poor reproductive history (Kutteh and Odom, 2012).  
2.4. Causes of recurrent pregnancy loss 
There are several causes for recurrent pregnancy loss that are identifiable and 
understood by medical science. However, in many couples the cause of RPL remains 
unexplained (Lavigne et al., 2005; Ford and Schust, 2009). 
2.4.1. Genetic / chromosomal causes 
Results from numerous studies in different countries have shown that in about 2-8% 
of couples with RPL, at least one of the partners has chromosomal abnormality. Most 
common abnormalities encountered are balanced reciprocal or Robertsonian 
translocations. Additional structural abnormalities associated with RPL include 
chromosomal inversions, insertions, and mosaicism (Ford and Schust, 2009; Sharif, 
2012). 
2.4.2. Anatomic / Uterine  abnormalities 
Anatomic abnormalities account for 10% to 15% of cases of RPL and are generally 
thought to cause miscarriage by interrupting the vasculature of the endometrium, 
prompting abnormal and inadequate placentation (Ford and Schust, 2009). Congenital 
uterine abnormalities include a double uterus, uterine septum, and a uterus in which 
only one side has formed. Asherman’s syndrome (scar tissue in the uterine cavity),  
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uterine fibroids, and possibly uterine polyps are acquired abnormalities that may also 
cause recurrent miscarriages. Some of these conditions may be surgically corrected 
(ASRM, 2008). 
2.4.3. Metabolic and Endocrine abnormalities 
Luteal phase defect (LPD), polycystic ovarian syndrome (PCOS), diabetes mellitus, 
thyroid disease, and hyperprolactinemia are among the endocrinologic disorders 
implicated in approximately 17% to 20% of  RPL (Ford and Schust, 2009). A number 
of designed studies have shown that neither polycystic ovaries  (PCO)  nor high 
luteinizing hormone (LH) levels are a cause for recurrent miscarriages (Clifford et 
al,1996; Rai et al., 2000; Nardo et al., 2002)  
2.4.4. Infectious causes 
The role of infection in recurrent miscarriage is unclear. Whilst bacterial vaginosis is 
associated with late pregnancy loss, preterm labor and premature rupture of membranes, 
its association with recurrent miscarriage is not known. Toxoplasmosis, rubella, 
cytomegalovirus, Chlamydia, herpes (collectively abbreviated as "TORCH") and 
Listeria infections are not thought to be infective causes of miscarriage. TORCH and 
bacterial vaginosis screening are considered by some authors as "not helpful" in the 
treatment of recurrent miscarriage (Horne and Alexander, 2005). 
2.4.5. Environmental and life style causes 
Smoking and alcohol consumption are both associated with miscarriage. Excessive 
coffee consumption may also increase the risk of miscarriage. It seems sensible to 
strongly recommend a healthy lifestyle and give advice regarding smoking, alcohol and 
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2.4.6. Immune causes 
Autoimmunity refers to an immune reaction of the body against substances that are 
normally present in the body. Numerous studies have attempted to identify specific 
autoantibodies associated with pregnancy loss (Kutteh and Odom, 2012). Because a 
fetus is not genetically identical to its mother, it is reasonable to infer that there are 
immunologic events that must occur to allow the mother to carry the fetus throughout 
gestation without rejection. In fact, there have been at least 10 such mechanisms 
proposed. It therefore follows that there may be abnormalities within these 
immunologic mechanisms that could lead to recurrent pregnancy loss (Ford and Schust, 
2009). Autoantibodies are more common in patients with recurrent miscarriage. The 
most common are antiphospholipid (14%) and antinuclear antibodies (7%), although the 
significance of the latter is uncertain. Thyroid antibodies have also been shown to be 
increased in women with recurrent miscarriage in a number of studies (Horne and 
Alexander, 2005). 
2.4.7. Thrombophilic causes 
The term thrombophilia is an umbrella term for a diverse group of blood clotting 
disorders of the haemostatic mechanisms (Dawood, 2011). The term was coined in 1965 
following a Norwegian familial study of venous thrombosis (Egeberg, 1965). Simmons 
(1997) described thrombophilia as a disorder in which there is a predisposition to 
thrombosis due to abnormally, enhanced coagulation and elsewhere they are described 
as disorders of the coagulation systems that are likely to predispose to thrombosis 
(Walker et al, 2001). Both inherited and combined inherited/ acquired thrombophilias 
are common, with more than 15% of the white population carrying an inherited 
thrombophilic mutation (Ford and Schust, 2009). The potential association between 
RPL and heritable thrombophilias is based on the theory that impaired placental 
development and function secondary to venous and/or arterial thrombosis could lead to  
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miscarriage (Ford and Schust, 2009). The heritable thrombophilias most often linked to 
RPL include hyperhomocysteinemia resulting from MTHFR mutations, activated 
protein C resistance associated with factor V Leiden mutations, protein C and protein S 
deficiencies, prothrombin promoter mutations, and antithrombin mutations. Acquired 
thrombophilias associated with RPL include hyperhomocysteinemia and activated 
protein C resistance (Ford and Schust, 2009). 
2.4.8. Unexplained causes 
In up to 50% of cases of recurrent miscarriage no causative factor is found. 
Fortunately, most of these women have an excellent prognosis for future pregnancy 
outcome if offered supportive care alone from a dedicated early pregnancy support 
clinic (Horne and Alexander, 2005). 
2.5. Thrombophilia 
2.5.1. Definition of thrombophilia 
Thrombophilia is defined as a disorder of hemostasis that predisposes a person to a 
thrombotic event. Data suggest that at least 50% of cases of venous thromboembolism 
in pregnant women are associated with an inherited or acquired thrombophilia (Carbone 
and Rampersad, 2010). Thrombophilias may be inherited or acquired, or have 
components of both types (Foy and Moll, 2009). 
2.5.2. Acquired Thrombophilia 
Acquired thrombophilia refers to a group of disorders that an individual is not born 
with, but may develop throughout his or her life due to another illness or situation. An 
example of acquired thrombophilia is the development of a lupus anticoagulant or 
antiphospholipid antibody syndrome. Several authors underlined the role of the 
antiphospholipid  syndrome (APS) in the pathophysiology of RPL (D’Uva et al.,2010). 
During APS, a large variety of autoantibodies also toward clotting factors, such as  
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factor XII, has been found (Jones et al., 2001; D’Uva et al., 2005). However, a clear 
explanation of all involved processes on the roles of antiphospholipid antibodies and of 
autoantibodies toward clotting factors is still matter of discussion (D’Uva et al.,2010). 
On the other hand, a role of increased maternal plasma levels of clotting factor VIII and 
the risk of RPL has been reported (Dossenbach - Glaninger et al., 2004). Furthermore, 
acquired activated protein C resistance, which is not associated with the presence of 
Factor V leiden (FVL), has been described in several women with RPL, but also in this 
case, not all involved mechanisms are known (Tal et al., 1999)  
2.5.3. Combined thrombophilia 
Combined thrombophilia, namely inherited thrombophilia associated with acquired 
thrombophilia or more than one inherited thrombophilic defect, has also been identified 
as a cause of RPL, but its real frequency is not clear. Several studies in the latest years 
identified combined thrombophilic defects in women with RPL both early RPL and late 
RPL (Gris et al., 1999; Robertson et al., 2006; Coulam et al., 2006). 
2.5.4. Hereditary thrombophilia 
Inherited thrombophilia occurs when an inherited DNA mutation results in the body 
producing: 
a) too much or too little of a blood clotting protein. 
b) a blood clotting protein that does not function correctly (Varga, 2005). 
There are a number of mutations that can cause inherited thrombophilia 
2.5.4.1. Factor V leiden 
Factor V leiden (FVL) mutation is the most common inherited thrombophilia and is 
present in about 5% to 9% of the white European population. FVL mutation is inherited 
in an autosomal dominant fashion and arises from a point mutation where glutamine is 
substituted for an arginine at position 506. This amino acid substitution impairs protein 
C and protein S activity; therefore, FVL is the leading cause of activated protein C  
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resistance (Carbone and Rampersad, 2010). The prevalence of heterozygosity for the 
factor V Leiden mutation in Europeans, Israeli, Arab, Canadian and Indian populations, 
ranges from 1 to 8.5 percent with most European studies reporting overall rates between 
5 and 8 percent. The prevalence is highest in Greece, Sweden, and Lebanon where it 
approximates 15 percent in some areas. On the other hand, the mutation is apparently 
not present in African Blacks, Chinese, or Japanese populations (Khan and Dickerman, 
2006). 
2.5.4.2 Factor V His1299Arg polymorphism  
Another polymorphism in the Factor V gene, the His1299Arg (H1299R) 
polymorphism, has been identified and linked to hereditary thrombophilia. In 1996 the 
Hl299R  polymorphism in exon 13 was first described (Lunghi et al., 1996). The Arg 
1299 (R2) allele was reported to be more frequent in subjects with reduced FV activity 
levels (De Visser et al., 2000). Another study reported that the R2 allele was associated 
with a reduced sensitivity for activated protein C (APC) (Bernardi et al., 1997). 
2.5.4.3. MTHFR  mutations 
Hyperhomocysteinemia can be seen with deficiencies in vitamins B6, B12, folic 
acid, and methylenehydrofolate reductase (MTHFR). Several mutations in the MTHFR 
gene (e.g., C677T and A1298C) can be a cause of mild to severe 
hyperhomocysteinemia. Homozygosity for MTHFR mutations is a relatively common 
cause of mildly elevated plasma homocysteine levels in the general population, often 
occurring in association with low serum folate levels, Homozygosity for MTHFR 
mutations is common worldwide with an estimated 10-25% prevalence among various 
ethnic backgrounds the risk of embryonic and fetal loss is increased if the MTHFR gene 
mutation is combined with additional thrombophilic factors (Rozano-Gorelick et al., 
2009; Carbone and Rampersad, 2010). 
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2.5.4.4. Prothrombin (factor II) gene (G20210A) mutation  
Heterozygosity for a mutation in the promoter of the prothrombin gene (G20210A), 
present in 2–3% of white European populations, leads to increased (150–200%) 
circulating levels of prothrombin and an increased risk of thromboembolism. This 
mutation accounts for 17% of thromboembolism in pregnancy. However, the actual risk 
of clotting in an asymptomatic pregnant carrier of this mutation is only 0.5%. The 
prothrombin (G20210A) mutation has been associated with an increased risk of fetal 
loss. Prothrombin gene mutation occurs due to a point mutation causing a guanine 
adenine substitution at nucleotide position 20210 (Lockwood, 2002; Carbone and 
Rampersad, 2010). 
2.5.4.5. Factor XIII gene polymorphism 
Factor XIII is an enzyme that catalyzes the formation of intermolecular epsilon (Ɣ -
glutamyl) –lysine covalent cross-links in fibrin. It also participates in other physiologic 
processes, including clot retraction, cell migration, and wound healing. There are four 
common forms of FXIII, resulting in amino acid changes at Val 34 Leu, Pro 564 Leu, 
Val 650 Ile, and Glu 651 Gln. The Val 34 Leu polymorphism results from a G100T 
coding alteration, and this alteration causes a change in amino acid structure in the A 
polypeptide chain 3 amino acids from the thrombin cleavage site, which occurs at 
Arg37- Gly38. Factor XIII disorder is inherited as an autosomal dominant trait with 
variable severity (Konecny, 2009). 
2.5.4.6. Plasminogen activator inhibitor 1 (PAI-1) gene 
Plasminogen activators are serine proteases which are part of an enzyme cascade 
converting plasminogen into plasmin. Urokinase plasminogen activator, its receptor, 
and PAI-1are believed to control proteolysis and remodeling of maternal tissue during 
trophoblast invasion. Plasma PAI-1 concentrations have been shown to be related to a  
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common guanosine insertion/deletion gene polymorphism, 4G/5G, 675bp upstream 
from the start site of translation. Homozygosity for the deletion genotype (4G/4G) has 
been associated with PAI-1 concentrations higher than those associated with the 
insertion genotype (5G/5G) and hence with reduced fibrinolytic activity (Al Sallout and 
Sharif, 2008). Glueck et al. (2001),stated that homozygosity for the 4G allele of the 
PAI-1 gene represents a serious risk for pregnancies. 
2.5.4.7. β-fibrinogen -455G>A gene polymorphism 
Fibrinogen (Factor I) is a glycoprotein, synthesized in the liver, that participates in 
the coagulation cascade. Fibrinogen converts to fibrin in the presence of thrombin. 
Elevated fibrinogen levels have been associated with increased risk for atherosclerosis 
and deep venous thrombosis as well as cardiovascular diseases. Fibrinogen is composed 
of three pairs of polypeptide chains (named α, β and γ) which are linked by disulfide 
bonds. Mutations in β-fibrinogen gene lead to several disorders, including 
afibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia and thrombotic tendency. 
The fibrinogen-raising beta-fibrinogen gene -455G/A polymorphism may enhance the 
physiological increase in fibrinogen levels during pregnancy and thereby predispose to 
obstetric complications (Leander et al., 2002). 
2.5.4.8. Integrin Beta-3 (Human platelet alloantigen-1) a/b gene 
polymorphism 
Thrombosis can also result from increased platelet aggregation and endothelial 
damage. Human platelets carry membrane glycοproteins that control platelet 
aggregation and activation. A number of clinical studies have suggested that certain 
polymorphisms of genes encοding these proteins increase the risk for cardiovascular 
disease (Chiras et al., 2009). Human platelet antigens (HPA) or Integrin Beta-3 are 
immunogenic polymorphic forms of platelet membrane glycoproteins (Tan et al., 2012).  
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The HPA-1 system is a biallelic system (either a or b), characterized by the presence 
of thymine or cytosine at base 196, respectively, which results in a leucine-to-proline 
substitution at position 33 of the protein leading to polymorphism in GpIIIa (HPA-1 
T196C, amino acid Leu33Pro) and is described as the PLA1/A2 alloantigen system 
(Chiras et al., 2009). Human platelet antigen-1a is by far the most frequently involved 
platelet antigen system in Caucasians accounting for 90% of cases, followed at a much 
lower frequency by HPA-5b (5-15%) and HPA-3a (Ahya et al., 2001). 
2.6. β-fibrinogen -455G>A gene polymorphism 
2.6.1. Fibrinogen protein and its structure 
Fibrinogen is the ultimate substrate protein of the coagulation cascade and forms the 
principal structural protein of the fibrin clot. Fibrinogen is a 340-kDa glycoprotein 
which is synthesized in hepatocytes and found in the human plasma at the level of 1.5 to 
3.5 g/l (Doolittle et al, 1979). Fibrinogen is a hexamer composed of two copies of three 
non identical protein chains, Aα, Bβ, and γ, that are disulfide-linked at their N-terminal 
ends by 29 disulphide bonds to form the circulating protein (Fort et al., 2011). During 
blood clotting, Thrombin cleaves small peptides, termed fibrinopeptides A and B, from 
the Aα and Bβ chains, respectively, to form a fibrin monomer. These monomers 
assemble into protofibrils in a half-staggered, side-to-side fashion that is stabilized by 
non-covalent interactions between fibrin molecules (Watanabe et al., 2003; Lefkowitz, 
2008).  
Since fibrinogen is an acute-phase protein, an increased plasma fibrinogen level may 
reflect the inflammatory state of the vascular wall and may thus be related to 
cardiovascular risk. However, a direct association between increased plasma fibrinogen 
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Levels of plasma fibrinogen rise rapidly in response to infection, inflammation, 
injury, or other trauma. Many other environmental factors are also associated with 
increased plasma fibrinogen levels. They include age, obesity, blood cholesterol, 
lipoprotein, hypertension, diabetes mellitus, and for women use of oral contraceptives. 
Diet does not influence fibrinogen levels, whereas smoking can dramatically increase 
them (Meade et al., 1979; Balleisen et al., 1985). 
2.6.2. Fibrinogen gene and Fibrinogen-β gene (FGB) 
Fibrinogen consists of 3 different polypeptide chains (known as α, β, and γ chains), 
which are encoded by 3 different genes cluster: FGA for A α , FGB for B β and FGG 
for γ, located in a 50-Kb cluster on chromosome 4 in region q28-31 (Fig. 2-1) (Xiang et 
al, 2008; Wypasek et al., 2012). In vitro studies have suggested that β-chain synthesis, 
which is regulated by a β-fibrinogen promoter, limits the rate of production of mature 
fibrinogen (Yu et al., 1984).  
 
Fig. 2-1: Location of fibrinogen gene on chromosome 4  
(Adopted from Genetic home Reference) 
2.6.2.1 Fibrinogen gene regulation   
The three genes undergo a degree of co-regulation to generate mRNA at balanced 
levels and sustain fibrinogen secretion from the liver. The FGB gene has eight exons 
and encodes a single mRNA. The FGA gene encodes two transcripts; the major isoform  
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from five exons yielding an mRNA encoding the Aα polypeptide, and a minor isoform 
(1–3%) from a six exon-derived transcript encoding the Aα E chain. The 6th exon of 
AαE encodes an additional COOH-terminal protein domain. The FGG transcript also 
undergoes alternative splicing with a major γ chain mRNA from 10 exons and a minor 
γ’ chain mRNA (about 10%), that does not splice intron 9, and replaces 4 exon 10 
encoded amino acids with 20 γ’ COOH-terminal residues (Fish and Arbez, 2012). Two 
studies reported that increasing the expression of a fibrinogen chain in HepG2 cells 
leads to coordinated up-regulation of the other chains (Roy et al., 1994; Roy et al., 
1990).  
The fibrinogen genes are expressed almost exclusively in hepatocytes where their 
output is coordinated to ensure a sufficient mRNA pool for each chain and maintain an 
abundant plasma fibrinogen protein level. Fibrinogen gene expression is controlled by 
the activity of proximal promoters which contain binding sites for hepatocyte 
transcription factors, including proteins which influence fibrinogen transcription in 
response to acute-phase inflammatory stimuli.  
In the general population fibrinogen level varies from about 1.5 to 3.5 g/l. This 
variation between individuals is influenced by genotype, suggesting there are genetic 
variants contributing to fibrinogen levels which reside in fibrinogen regulatory loci 
(Fish and Arbez, 2012).  
2.6.3. β-fibrinogen gene polymorphism 
Several studies evaluated potential associations between polymorphisms in the β-
fibrinogen gene and plasma fibrinogen levels (Van Hooft et al.,1999). At least 10 
common single nucleotide polymorphisms (SNPs) have been described (Thomas et al., 
1991; Fowkes et al., 1992; Baumann et al., 1993; Behague et al., 1996), for example, β 
148C/T, β 249C/T, β 455G/A, β 854G/A, and β 993C/T. Several of these are associated 
with increased plasma fibrinogen concentrations, suggesting that genetic variation in the  
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β-fibrinogen gene can contribute to the regulation of plasma fibrinogen levels. 
However, it was also observed that some of these polymorphisms are in linkage 
disequilibrium (Baumann and Henschen, 1994; Behague et al., 1996) which makes it 
difficult to determine the physiological significance of the different mutations. 
2.6.3.1. β-fibrinogen gene -455G>A polymorphism 
A common G>A polymorphism at position -455 in the promoter region of the β-
fibrinogen gene has been associated with elevated fibrinogen levels for the AA 
homozygotes (Van Hooft et al., 1999; Van Goor et al., 2005; Wypasek et al., 2012). 
Carriers of the -455A allele at this polymorphic site, about 20% of the population, have 
been suggested to have about 7–10% higher fibrinogen levels than those homozygous 
for the -455G allele (Leander et al., 2002).  
Healthy individuals who are homozygous for the rare alleles of β-gene 
polymorphisms have the highest fibrinogen levels; individuals who are homozygous for 
the common allele have the lowest plasma fibrinogen levels, while the fibrinogen levels 
in heterozygotes are intermediate (Humphries et al., 1987; Cook et al., 1988; Berg et al., 
1989; Green et al., 1993). 
2.7. Integrin Beta-3 (Human platelet alloantigen-1) a/b gene 
polymorphism 
2.7.1. Integrin Beta-3 and its structure 
Integrins are heterodimers composed of an alpha and beta subunit. Each subunit has 
a large extracellular domain, a single transmembrane domain and a short cytoplasmic 
domain (Fernandez  et al., 1998). Integrins family contains 18α and 8 β subunits that 
bind non-covalently to form 24 distinct α β integrin heterodimers with each β subunit 
binding several α subunits (Xiao et al., 2004). 
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The ITGB3 protein product is the integrin beta chain beta 3, beta 3 chain may 
combine with multiple partners resulting in different integrins. Integrin beta 3 is found 
along with the alpha IIb chain in platelets. Integrins are known to participate in cell 
adhesion as well as cell-surface mediated signaling (Anderson et al., 2013).  
GPIIIa (CD61, b3) is a glycosylated 90-kDa single protein consisting of three 
domains: a large extracellular N-terminal region which is highly cross-linked by 28 
disulfide bonds; a transmembrane domain; and a short cytoplasmic C-terminal segment 
(Rozman, 2002). 
The platelet membrane glycoprotein IIb/IIIa heterodimer complex (GPIIb / IIIa) 
(β3αIIb) is the platelet receptor for adhesive proteins, containing binding sites for 
fibrinogen, von Willebrand factor (vWf), and fibronectin on activated platelets. The 
GPIIb / IIIa is the most abundant platelet cell-surface protein, There are approximately 




ions for its 
function and structure (Fig 2-2) (Poncz et al., 1987; Phillips et al., 1987; Zimrin et al., 
1988).  
As a result, GP complex GPIIb-IIIa (aIIb b3) is involved in the spreading of platelets 
by binding to the circulating von Willebrand’s factor and fibrinogen, allowing platelet-
to-platelet interaction (Roz˘man, 2002) 
The GPIIb/IIIa complex functions as the aggregation site on the platelet membrane 
surface. Upon platelet activation, GPIIb/IIIa undergoes a conformational change that 
permits fibrinogen to bind. Following activation integrin alpha-IIb/beta-3 brings about 
platelet/platelet interaction through binding of soluble fibrinogen. This step leads to 
rapid platelet aggregation which physically plugs ruptured endothelial surface (Phillips 
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Fig 2-2: Model of the GPIIb/IIIa complex inserted into the lipid bilayer  
(Adopted from Phillips et al.,1988) 
2.7.2. Integrin beta-3 gene  
The official name of this gene is “integrin beta-3 (platelet glycoprotein IIIa, antigen 
CD61).” ITGB3 is the gene's official symbol. The ITGB3 gene is also known by other 
names such as (BDPLT2, BDPLT16, CD61, GP3A, GPIIIa).  The integrin b3 gene 
encodes glycoprotein IIIa (GP IIIa) which is part of GP IIb/IIIa complex when activated 
interacts with fibrinogen to cross-link platelets to one another and causes platelet 
aggregation (Curtis, 2008). The genes coding for GPs IIb and IIIa are located on the 
long arm of chromosome 17 at region q 21.32, within a single 260-kb segment (Fig. 2-
3) (Metcalfe, 2004). 
 
Fig. 2-3: location of Integrin beta 3 gene (Adopted from Genetic home Reference) 
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More precisely, the ITGB3 gene is located from base pair 45,331,207 to base pair 
45,390,076 on chromosome 17. 
In 1974, Nurden and Caen have made a key observation that the functional defects of 
platelet glycoprotein GPIIbyIIIa were the cause of Glanzmann’s thrombasthenia 
(Nurden and Caen, 1974) 
Rare haemorrhagic syndrome, Glanzmann Thrombasthenia, an exceptional inherited 
platelet disorder is characterized by a complete lack of platelet aggregation due to a 
defect in the alpha(IIb)beta3 complex or to a qualitative abnormality of this complex. 
Advances in molecular biology have permitted to precise the molecular abnormality on 
alpha(IIb) or beta3 genes responsible for the disease and have also contributed to a 
better knowledge of normal platelet physiology (Hogg and Bates, 2000; Bellucci and 
Caen, 2002). 
 2.7.2.1. Integrin beta-3 gene regulation by HOMEOBOX gene (HOXA10) in 
Endometrial Cells 
The HOMEOBOX gene Hoxa10 is expressed in the murine endometrium and is 
essential for fertility in mice. Estrogen and progesterone regulate HOXA10 expression 
in the endometrium, where HOXA10 is necessary for implantation. The integrins are 
also involved in early embryo-endometrial interactions. Daftary et al., showed that 
HOXA10 directly regulates β3 integrin subunit expression in the endometrium, likely 
mediating the effect of sex steroids on β3 integrin expression. β3-Integrin expression 
was decreased in endometrium shown to have low HOXA10 expression. β3-Integrin 
mRNA levels were increased in endometrial adenocarcinoma cells transfected with 
pcDNA3.1/HOXA10, and decreased in cells treated with HOXA10 antisense (Daftary et 
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2.7.3. Integrin beta-3 gene polymorphisms 
The complementary DNA (cDNA) coding for the glycoproteins on which the 
alloantigens of HPA- 1, 2, 3 and 4 localized has been cloned and sequenced, and the 
DNA base changes (polymorphisms) corresponding to the serologically defined allelic 
variations were determined (Fitzgerald et al.,1987a and b; Lopez et al., 1987). In studies 
using either cDNA obtained by transcribing mRNA isolated from phenotyped platelets, 
or genomic DNA from mononuclear cells, the difference between the two alleles has 
been shown to be a single base pair substitution corresponding to one amino acid 
difference in the relevant glycoprotein (Table 2-1). 





a      b 
Codon 
a         b 
Amino acid substitution and postion 
         a               b 
Reference 
1 IIIa T→C CTG→CCG Lencine→Proline(33) Newman et al., (1989) 
2 Ib C→T ACG→ATG Threonine→Methionine(145) Kuijpers et al., (1992) 
3 IIb T→G ATC→AGC Isoleucine → Serine(843) Lyman et al., (1990) 
4 IIIa G→A CGA→CAA Arginine → Glutamine(143) Wang et al., (1991) 
 
2.7.3.1. Integrin beta-3 a/b (L33P)  gene polymorphism 
The human platelet antigen (HPA)-1 alloimmune system, carried by the platelet 
integrin αIIbβ3 (GP IIbIIIa), is of major clinical interest. It is the first cause of 
alloimmune thrombocytopenia in Caucasian populations and the allele HPA-1b may be 
a risk factor for thrombosis. This alloantigenic system is characterized by a leucine-to-
proline substitution in position 33 of the mature β3 subunit of the αIIbβ3 integrin, 
changing allele HPA-1a into HPA-1b (Newman et al., 1989). Nonetheless, alloimmune  
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responses to the HPA-1a and HPA-1b variants have been shown to be complex and to 
differ in their frequencies (Kuijpers et al., 1992) Similarly, association between the 
HPA-1b variant and a thrombosis risk factor is still debated (Di Castelnuovo et al., 
2001) and, although experimental data have suggested enhanced platelet functions 
(Vijayan et al., 2006) the mechanism that potentially leads to thrombosis remains to be 
elucidated. 
The polymorphic rs5918 variant (Leu33Pro) of the ITGB3 thrombocyte receptor 
gene was indicated that the substitution of the amino acid leucine for proline, which 
results in an increase in the aggregation capabilities of thrombocytes is associated with 
myocardium infarction, coronary atherosclerosis (Knowles et al., 2007; Kucharska, 
2011), coronary stent thrombosis, acute coronary syndrome (Cayla et al.,2011) and 
stroke (Stankovic et al., 2010) and influences the decrease in the efficiency of some 
anti-aggregants, such as aspirin and clopidogrel (Goodman et al., 2008) In addition, it 
was indicated that the presence of the polymorphic 33Pro variant, designated as PLA2, 
is a risk factor in the development of obstetric pathologies, including implantation 
failure, the development of preeclampsia, and placental insufficiency (Yenicesu et al., 
2010) 
2.8. Previous Studies 
Coulam et al. (2006) compared the prevalence of 10 thrombophilic gene 
polymorphisms (FV Leiden, FV 4070A/G, FV 5279A/G, Factor II prothrombin 20210 
G/A, FXIII 103G/T, BF-455G/A, PAI-1 4G/5G, ITGB3 1565T/C, MTHFR 677C/T, 
MTHFR 1298A/C) in 75 patients with a history of recurrent miscarriage with 14 fertile 
control women and found no differences between the two groups. However, the 
prevalence of total gene polymorphisms among patients with recurrent miscarriage was 
significantly higher than that of the controls. They also reported that more than three 
gene polymorphisms, among the 10 studied genes, existed in 68% of women with  
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recurrent miscarriage and in 21% of the controls (Relative risk: 0.4073, 95% CI 0.2653–
0.6253, p <0.001)., so inherited thrombophilias are associated with recurrent 
miscarriage, This association is manifested by total number of mutations rather than 
specific genes involved.  
Ozdemir et al. (2011) showed that no meaningful association between RPL and 
HPA-1 a/b or  β–fibrinogen -455G>A gene polymorphism. 
 In 2010, Yenicesu et al. showed that heterozygous mutations of GPIIIa L33P were 
associated with RPL and there was no meaningful association between RPL and β-
fibrinogen -455G>A gene polymorphism. 
Goodman et al. (2006) showed that a panel of thrombogenic gene mutations 
consisting of factor V G1691A, factor V H1299R (R2), factor II prothrombin G20210A, 
factor XIII V34L, beta-fibrinogen -455G>A, PAI-1 4G/5G, HPA1 a/b (L33P), MTHFR 
C677T, and MTHFR A1298C can identify individuals at risk for recurrent pregnancy 
loss. Women with a history of RPL demonstrated significantly higher numbers of 
polymorphism than the controls (p <0. 001). 
Coulam et al. (2008) compared the frequencies of nine inherited thrombophilias 
including factor V G1691A, factor V H1299R (R2), factor II Prothrombin G20210A, 
factor XIII V34L, beta-fibrinogen -455G>A, PAI-1 4G/5G, human platelet antigen 1 a/b 
(L33P), MTHFR C677T, MTHFR A1298C among women with a history of recurrent 
pregnancy loss with individuals experiencing deep venous thrombosis (DVT) and fertile 
controls. Their study showed that individuals with a history of DVT had a significantly 
higher frequency of all of the polymorphisms studied compared with women 
experiencing a history of recurrent pregnancy loss and the fertile controls. The 
frequencies of mutations factor XIII V34L and PAI-1 4G/5G were significantly 
increased among women experiencing recurrent pregnancy loss compared with controls. 
The most prevalent polymorphisms were factor XIII V34L and PAI-1 4G/4G for both  
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individuals with a history of deep vein thrombosis and recurrent pregnancy loss as 
compared to controls.  
Pihusch et al. (2001) showed that no differences in the prevalence of FVL, MTHFR 
T/T, GPIIIa and 1-fibrinogen polymorphism were detected. Heterozygous prothrombin 
G20210A mutation (PTM), however, occurred more often in patients with recurrent 
spontaneous abortions.  
Torabi et al. (2012) studied 100 patients with RM compared with 100 controls 
without RM, Torabi et al., found that  the β-Fibrinogen -455G/A  gene polymorphism is 
associated with RPL. 
Reiner et al. (2001) suggested that the glycoprotein IIIa Leu33Pro amino acid 
substitution was associated with a subtle effect on platelet thrombogenicity in vitro. The 
Leu33Pro allele seems to cause structural changes in the GPIIb/IIIa receptor which may 
in turn lead to a different ligand binding of the active GPIIb/IIIa receptor. However, 
Reiner et al concluded that it is not a major risk factor for arterial thrombotic disease 
among the general population. 
Since Weiss et al. (1996) for the first time reported that the gene frequency of the 
HPA-1b allele of integrin αIIbβ3 was significantly higher among young patients with 
myocardial infarction compared with age-matched controls (Weiss et al,1996), 
numerous clinical studies were conducted in order to define a role of related 
polymorphisms in arterial thrombosis. Surprisingly, these studies gave different, and in 
some cases, contradictory results (Zotz et al.,1998; Streifler et al.,2001; Zotz et al, 
2005). Zotz et al. (1998) showed that, the prevalence of HPA-1b was higher among 
patients with acute or recent onset myocardial infarction (< 1 year) than among patients 
with coronary artery disease but without myocardial infarction (33 percent vs. 14 
percent, p = 0.016). In patients under 60 years of age this difference was even more  
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pronounced (45 percent vs. 15 percent, p = 0.003). Unlike conventional risk factors 
HPA-1b does not represent a risk factor for coronary artery disease itself but appears to 
be associated with increased platelet thrombogenicity. 
Zotz et al. (2005) found that the median age of onset of myocardial infarction was 
5.2 years earlier (P = 0.006) in carriers of the HPA-1b allele and 6.3 years earlier (P = 
0.006) in carriers of the alpha(2)807TT genotype in the 264 survivors of myocardial 
infarction of recent onset with one- or two-vessel coronary artery disease. A significant 
interaction with the conventional risk factors hypercholesterolemia, smoking, diabetes, 
hypertension, and hyperfibrinogenemia was excluded. Human platelet antigen 1b and 
alpha(2)807TT are associated with premature myocardial infarction but not with 
coronary artery disease, suggesting a role of distinct integrin genotypes for increased 
platelet thrombogenicity (Zotz et al., 2005). 
In 2001, Streifler et al. concluded that hyperhomocysteinemia and HPA-1a/b (L33P) 
are independent risk factors for ischemic events in patients with significant carotid 
stenosis (Streifler et al.,2001). 
In 2013, Goncharova et al.’s  study indicated that the PLA2 allele and PLA2/PLA2 
rs5918 genotype of the ITGB3 gene in Russian women from the Siberian region is 
associated with recurrent miscarriage (Goncharova et al., 2013). 
Zito et al. described a positive association of the (- 455) A allele with MI in a small 
number of patients (Zito et al., 1997) . In the meta-analysis by Boekholdt et al., carriers 
of the fibrinogen (-455) AA genotype who had statistically significantly higher 
fibrinogen levels even had a decreased risk for MI (Boekholdt et al.,2001). 
In 2005, Smith et al. performed a meta-analysis and found that FgB -455G/A, -
148C/T gene polymorphism were not associated with coronary artery disease (CAD) 
(Smith et al, 2005).  
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In 2007, Sun et al. found an association between FgB -455G/A, -148C/T gene 
polymorphism and CAD and they concluded that -455A, -148T might represent a 
genetic risk factor for CAD (Sun et al., 2007). However, Zhang et al. found that FgB -
455G/ A was not correlated to the risk of CAD (Zhang et al.,2000). Ma et al. found that 
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3.1. Materials 
3.1.1. Chemicals and reagents  
Chemicals and reagents used in this study are shown in Table (3-1). All chemicals were 
of analytical and molecular biology grade. 
Table 3-1: Chemicals and reagents 
# Reagent Supplier 
1.  Wizard ® Genomic DNA Purification Kit Promega (Madison, USA) 
2.  PCR Go Taq® Green Master Mix   Promega (Madison, USA) 
3.  Agarose  Promega (Madison, USA) 
4.  PCR primers Promega (Madison, USA) 
5.  HaeIII Restriction enzyme Promega (Madison, USA) 
6.  Nuclease free water Promega (Madison, USA) 
7.  Ethidium bromide Promega (Madison, USA) 
8.  Ethanol 70%  (Sigma USA). 





Chapter (3)                   Materials and Methods 
3.1.2. Instruments and Disposables 
The present work was carried out in the Genetics lab at the Islamic University of Gaza. 
The important instruments and disposables used in the present study are listed in Table 
(3-2): 
Table 3-2: Instruments and disposables 
# Instrument Manufacturer 
1.  Thermal Cycler Eppendrof, Germany 
2.  Electrophoresis chambers and tanks (horizontal) BioRad, USA 
3.  Electrophoresis power supply BioRad, USA 
4.  Microcentrifuge Sanyo, UK 
5.  Microwave Oven L.G, Korea 
6.  Digital balance AE adam, USA 
7.  Freezer, refrigerator ORSO, pharml-spain 
8.  Micropipettes (0.1-2.5μl / 0.5-10μl / 5-50μl / 20-200μl / 100-1000μl) Dragon-lab, USA 
9.  Safety cabinet N-Biotek,Inc 
10.  Gel documentation system Vision, Scie-Plas Ltd, UK 
11.  Microfuge tubes for PCR - thin wall 0.2 mL capacity Labcon, USA 
12.  Microfuge tubes - 1.5 mL capacity Labcon, USA 
13.  EDTA tubes Hy. Labs. Israel 
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3.1.3. PCR primers 
All PCR primers are indicated from 5' to 3' end. Sense primers are marked with (F) 
while antisense primers are marked with (R). The primer sequences were obtained from 
published studies and are provided in (Table 3-3). 
Table 3-3: Nucleotide sequence of the PCR primers 
Gene Primer sequence Reference 
FGB -455 G/A 
Forward 5’- AGGGTCTTTCTGATGTGT-3’ 
(Xiang-feng et 
al, 2008) 




HPA-1a 5’-TCACAGCGAGGTGAGGCCA - 3’ 





3.2. Study population 
3.2.1. Study design 
The current study is a case-control study, in which women with RM were compared to 
women without any evidence of RM.  
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3.2.3. Characteristics of the Study population 
From May 2013 to July 2013,  a total of 102 women as a study group and 97 as a 
control group from different areas of Gaza strip whose parents were of the same 
ethnicity (Palestinian people)  were included in the study. 
For the study group, all 102 patients were from the Genetics lab of the Islamic 
university of Gaza. The study group included women aged 19-35 years who had 
experienced at least three unexplained consecutive spontaneous miscarriages before 25 
weeks of gestation with primary RM (without a live birth) or secondary (a live birth 
followed by consecutive spontaneous abortions). All subjects  were investigated more 
than two months after the last pregnancy.  
All the study women were those referred as having unexplained or idiopathic RM by 
specialists in hospitals or private clinics. 
The control group included a total of 97 healthy women who had delivered at least one 
healthy, term infant and had no history of pregnancy loss. Controls were matched for 
ethnic background. None of the controls used oral contraceptives, hormonal, 
intrauterine devices, or any medication affecting liver function and/or blood 
coagulation. 
3.2.4. Ethical consideration 
An authorization to carry out the study was obtained from the local ethics committee 
using an agreement letter prepared from the Islamic University of Gaza. Informed 
consent was taken from all the subjects who participated in the study. The objective of 
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3.3. Methods 
All polymorphisms were tested in the Genetics lab of the Islamic University. 
3.3.1. Sample collection  
About 2.0 ml of venous blood were drawn into sterile EDTA tubes and mixed gently, 
under quality control and safety procedure. EDTA tube was used for genomic DNA 
extraction. The blood samples were then stored at -70°C until time of DNA  extraction 
and purification. 
3.3.2. DNA extraction 
3.3.2.1. DNA purification 
Genomic DNA was isolated from blood using Wizard Genomic DNA Purification Kit 
(Promega, USA), the contents of which are given in (Table 3-4), according to the 
manufacturer's protocol. The materials that should be supplied by the user are indicated 
in (Table 3-5). 
Table 3-4: Wizard genomic DNA purification kit solutions. 
# Solutions Volume 
1.  Cell lysis Solution 100ml 
2.  Nuclei lysis Solution 50ml 
3.  Protein precipitation Solution 25ml 
4.  DNA rehydration Solution 50ml 
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Table 3-5: Materials that should be supplied by the user 
# Materials 
1.  Sterile 1.5 ml microcentrifuge tubes 
2.  Water bath, (37oC, 65 oC) 
3.  Isopropanol, room temperature. 
4.  70% ethanol, room temperature. 
5.  Microcentrifuge. 
6.  Sterile 1.5 ml microcentrifuge tubes 
7.  Water bath, (37oC, 65 oC) 
 
3.3.2.1.1 Procedure of Extracting DNA from Blood (Isolation of genomic 
DNA): 
1. A volume of 300 μl well mixed blood were added to 1.5 ml microcentrifuge tube  
containing 900 μl of cell lysis solution (lyses the red blood cells and white blood 
cells)  mixed by inverting the tube gently and the mixture was incubated at room 
temperature for 10 minutes. During the incubation period the tube was periodically 
mixed (2-3 times) by inversion. 
2. The mixture was centrifuged at 13,000 rpm for 20 seconds, then the supernatant was 
removed and discarded without disrupting the visible white pellet, after that the 
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3. A volume of 300 μl nuclei lysis solution (lyses the nuclear membrane of white 
blood cells nuclei) were added to the resuspend pellet with pipeting the solution 5-6 
times. The solution should become very viscous; the sample with visible clumps 
should be incubated at 37°C until the clumps are disrupted. 
4.  A volume of 1.5 μl RNase solution (digest the RNA ) was added to the nuclear 
lysate and they were mixed by inverting 2-5 times, then incubated at 37°C for 15 
minutes, and the mixture was cooled to room temperature . 
5. One hundred μl protein precipitation solution (precipitates all the cellular and 
nuclear proteins) were added  to the cooled nuclear lysate and they were mixed 
vigorously for 10-20 seconds by the vortex – small proteins clumps may be visible 
after vortexing – then centrifuged at 13,000 rpm for 3 minutes. A dark brown 
proteins pellet should be visible. 
6. The supernatant was then transferred to a clean 1.5 ml microcentrifuge tube 
containing 300 μl isoprobanol  and was mixed gently by inversion until white thread 
– like strand of DNA from a visible mass, then centrifuged at 13,000 rpm for 1 
minute. The DNA will be visible as a small  white pellet.  
7. The supernatant was removed and 300 μl of 70 % ethanol were added to the small 
white pellet and gently inverted several times to wash the DNA pellet then 
centrifuged at 13,000 rpm for 1 minute. 
8. The ethanol was aspirated carefully using micropipette, and then the tube was 
inverted on a clean absorbent proper. The pellet was air dried for 10-15 minutes. 
9. The DNA pellet was rehydrated  by addition of 100 μl rehydration solution and 
incubated at 65°C for 1 hour. The DNA pellet should be mixed periodically by 
gently tapping the tube.  
10. Finally the DNA was stored at 2-8° C until PCR analysis. 
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3.3.2.2. Detection and quantition of extracted DNA 
The quality of the isolated DNA was determined by running 5 μl of each sample on 
ethidium bromide stained 1.0% agarose gel. The DNA sample was then visualized on a 
Gel documentation system. 
3.3.3. Genotyping 
3.3.3.1. Primers reconstitution 
The primers were reconstituted at 2.0 µmol concentration. Primer containers were first 
centrifuged at 13,000 rpm for 3 minutes, and then reconstituted with ultra pure water, 
vortexed and diluted by transfer of 5 µL of each reconstitute to a new clean sterile 
labeled microfuge tube containing 45 µL of ultra pure water, to be at a final 
concentration of 2.0 µmol. 
3.3.3.2. Determination of β-fibrinogen - 455G>A Polymorphism 
Polymorphism of -455G>A fibrinogen was genotyped using standard polymerase chain 
reaction (PCR)/restriction fragment length polymorphism (RFLP) protocol (PCR 
followed by digestion with restriction enzyme). The primers, lengths of PCR products, 
related restriction enzymes, as well as digested bands are shown in (Table 3-6). PCR 
products were digested with restriction enzymes following the manufacturer’s 
instructions. 
Table 3-6: Primer sequences and restriction enzymes for -455G>A fibrinogen 






336 bp HaeIII 
A allele 336 bp 
G allele 215+121 bp 
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3.3.3.2.1. -455 G>A β- fibrinogen PCR-RFLP procedure: 
3.3.3.2.1. 1. Polymerase Chain Reaction (PCR) for -455G>A β- fibrinogen: 
Polymerase chain reaction (PCR) was carried out in a total volume of 20 μl, the reaction 
components were as described in (Table 3-7). 
Table 3-7: PCR components for amplification of the β-fibrinogen -455G>A 
Polymorphism 
Reagent Volume (μl) Final concentration 
Forward primer 2 20 pmol 
Reverse primer 2 20 pmol 
Nuclease free water 4 - 
PCR mastermix 10 1X 
DNA 2 100ng 
 
Microfuge tubes were then placed in a thermocycler and PCR amplification was started 
according to the program provided in (Table 3-8). 
Table 3-8: Thermocycler program for PCR amplification of the β-fibrinogen-455G 
>A polymorphism. 
No. of cycles Temperature (ºC) Time 
1 95 5 min. 
35 
94 40 sec. 
53 40 sec. 
72 40 sec. 
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3.3.3.2.1.2 Restriction Fragment Length Polymorphism (RFLP) by HaeIII 
restriction enzyme 
RFLP of β-fibrinogen - 455G>A Polymorphism was carried out in a reaction mixture in 
a final volume of 10μl by mixing PCR product with 10X Buffer C, MULTI-CORE 
Buffer, BSA, nuclease free water and the restriction endonuclease HaeIII. The 
quantities and volumes were as shown in (Table 3-9). 
Table 3-9: The enzymatic digestion components of amplified -455G>A β-
fibrinogen gene 
Reagent Volume (μl) Final concentration 
PCR product 10 3µg 
10X Buffer C 2 1X 
Restriction endonuclease HaeIII 0.5 1u/1 µg 
MULTI - CORE Buffer 2 1X 
Acetylated BSA 2 1X 
Nuclease free water 3.5 - 
 
Microfuge tubes were then placed in a thermocycler at 37ºC overnight to allow the 
restriction endonuclease to digest the PCR product. Figure 3-1 shows the mechanism of 
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Figure 3-1: The PCR-RFLP principle of detecting mutant and wild type alleles. 
I. Heterozygote: three bands indicating that half of the PCR products were cut 
(normal allele) and the other half weren't (abnormal allele). 
II. Homozygote for normal allele: two bands indicating that the product was 
completely cleaved while 
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Figure 3-2: The recognition site for HaeIII restriction enzyme 
Digested PCR product was then electrophoresed on 2.0% agarose gel and was 
visualized by ethidium bromide staining. 
3.3.3.2.2. Agarose gel electrophoresis (2.0%) 
1. Dried agarose gel (1.2 gm) was dissolved in 60 ml 1x Tirs-Acetate-EDTA buffer 
(2M Tris base 1M Glacial Acetic Acid, 0.05 M EDTA) by heating.  
2. Then 2.5μl Ethidium Bromide was added and mixed, the gel was casted into a mold 
which was fitted with a well forming comb.  
3. The agarose gel was submerged in electrophoresis buffer within a horizontal 
electrophoresis apparatus.  
4. After amplification, the PCR products and a DNA ladder size marker (Promega, 
Madison, WI, USA) were loaded into the sample wells to aid in fragment size 
determination.  
5. PCR fragments were detected by size in the agarose gel. 
6. Electrophoresis was performed by using Electrophoresis power supply (BioRad, 
USA) at 70 volts for 40 min at room temperature, and the DNA bands were 
visualized and documented using a UV trans-illuminator documentation system.  
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For - 455G>A detection, a segment of promoter region in chromosome 4 which 
contains the base pair substitution -455G>A was amplified using the primer set 
presented in Table 3-6 and the PCR product (336 bp) was restricted using HaeIII 
restriction enzyme which cuts the wild allele into two segments (215 bp and 121bp) but 
doesn't cut the mutant allele. Homozygous for  the mutant allele should yield one band 
(336 bp) while the heterozygotes should produce three bands (336 bp, 215 bp, and 121 
bp). Homozygotes for the normal allele should give two bands (215 bp and 121 bp).  
3.3.3.3. Determination of Integrin beta-3 a/b(L33P) Polymorphism 
Integrin beta-3 "HPA" a/b (L33P) polymorphism was genotyped using PCR sequence- 
specific primers (PCR-SSP), which uses two reactions with two sets of primers: one 
primer is specific for each allele (allele-specific primer) and is paired with a second 
common primer to control for PCR efficiency. The basis of this method is the reduction 
in the efficiency of Taq polymerase to amplify DNA when there is a 3’ terminal 
nucleotide mismatch between the target DNA and the allele-specific primer. The HPA 
genotype is identified by the presence or absence of DNA bands after gel 
electrophoresis of the PCR products. This method is a relatively simple and inexpensive 
procedure for HPA genotyping. 
3.3.3.3.1. PCR-SSP procedure for Integrin beta-3 a/b polymorphism 
Polymerase chain reaction (PCR) was carried out in a total volume of 20 μl. The 
primers, lengths of PCR products, are shown in (Table 3-10) and the reaction 
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Table 3-10: primers and lengths of PCR products for Integrin beta-3 a/b 
polymorphism 
Primer sequences PCR products size (bp) 
HPA-1a 5’ TCACAGCGAGGTGAGGCCA 3’ 90 
Common-1 5’ GGAGGTAGAGAGTCGCCATAG 3’   
HPA-1b 5’ TCACAGCGAGGTGAGGCCG 3’ 90 
 
Table 3-11: PCR components for amplification of the Integrin beta-3 a/b 
Polymorphism 
Reagent Volume (μ𝐥) Final concentration 
Common primer 2 20 pmol 
HPA-1a primer / HPA-1b primer 2 20 pmol 
Nuclease free water 4 - 
PCR master mix 10 1X 
DNA  2 100ng 
Total  20  
 
Microfuge tubes were then placed in a thermocycler and PCR amplification was started 
according to the program provided in (Table 3-12). 
Table 3-12: Thermocycler program for PCR amplification of the Integrin beta-3 
a/b polymorphism 
No. of cycles Temperature (ºC) Time 
1 96 1 min 
25 
96 25 sec 
68 45 sec 
72 30 sec 
1 72 3 min 
 
The amplified  products were electrophoresed on 2.0% agarose gel (prepared as 
described in section 3.3.3.2.4.) and was visualized by ethidium bromide staining. 
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3.4 Statistical analysis 
The Hardy-Weinberg equilibrium (HWE) equation was used to calculate the expected 
genotype frequency. Difference between expected and observed genotypes was assessed 
by X
2
 test. P-value less than 0.05 was considered statistically significant.The 
frequencies of the alleles and genotypes were compared between patient and control 
groups by the Chi square test when appropriate. The odds ratio (OR) and 95% 
confidence interval (CI) were also estimated in order to test the relation between RPL 
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4.1. PCR Genotyping results 
The following figures are representative examples of the β-fibrinogen -455G>A and 
Integrin Beta-3(HPA-1) a/b gene polymorphisms investigated in this study. 
Figures (4-1) and (4-2), show representative PCR results for the genotyping of the β-
fibrinogen -455G>A and Integrin Beta-3 a/b gene polymorphisms, respectively. 
 
Fig 4-1: A photograph of ethidium bromide stained 2% agarose gel showing 
the RFLP-PCR product for β – fibrinogen -455G>A polymorphism, M= 
50bp DNA ladder, lane1 indicates a homozygous sample for GG, lane 2 
indicates a heterozygous GA and lane 3 indicates a homozygous AA. 
 
 
Fig 4-2: A photograph of ethidium bromide stained 2% agrarose gel 
showing the PCR-SSP product for Integrin Beta-3 a/b polymorphisms, 
sample 1 indicates a heterozygous ab, sample 2 indicates homozygous aa,  
sample 3 indicates homozygous bb and sample 4 indicates control. 
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4.2. β –fibrinogen 455G>A gene polymorphism: 
4.2.1.  Genotype frequency of the β–fibrinogen 455G>A polymorphism 
among RPL patients and controls 
Table (4 -1) and (Fig. 4-3) illustrate the genotype frequencies of the β–fibrinogen 
455G>A gene polymorphism among RPL patients. The frequency of the wild type GG 
was 68.6 %, the frequency of the heterozygote GA was 27.5% while, the frequency of 
the homozygotes for the polymorphic allele AA was 3.9% in RPL women.    
Table 4-1: Frequency of genotypes of β–fibrinogen 455G>A polymorphism among 
RPL patients 
Genotype Frequency Percent % 
AA 4 3.9 
GA 28 27.5 
GG 70 68.6 
Total 102 100.0 
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Table (4 -2) and (Fig. 4-4) illustrate the frequencies of genotype of  the β–fibrinogen 
455G>A gene polymorphism among control women. The frequency of the wild type 
GG was 63.9 %, the frequency of the heterozygotes (GA) was 32.0 % while, the 
frequency of the homozygotes for polymorphic allele AA was 4.1%.    
Table 4-2: Frequency of genotypes of β–fibrinogen 455G>A polymorphism among 
control women 
Genotype  Frequency Percent % 
AA 4 4.1 
GA 31 32.0 
GG 62 63.9 
Total 97 100.0 
 
 
Fig 4-4: Frequency of genotypes of β–fibrinogen 455G>A polymorphism among 
control women 
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Table (4-3) illustrates genotypes frequency, odd ratio (OR), 95% confidence intervals 
(CI) and P value of the β–fibrinogen 455G>A gene polymorphism among RPL patients 
and controls. The statistical analysis of frequency of the β-fibrinogen 455G>A gene 
polymorphism among RPL patients and control showed that the difference was not 
significant in the three genotype AA, GA, and GG between the two groups. 
Table 4-3: Genotype frequency of β–fibrinogen 455G>A gene polymorphism 






























   
 
4.2.2.  Alleles frequency of the β–fibrinogen 455G>A polymorphism among 
RPL patients and controls 
Table (4-4) illustrates alleles frequency, odds ratio, 95% confidence intervals and P 
value  of β–fibrinogen 455G>A polymorphism among RPL patients and controls. The 
statistical analysis of allele frequency of the β–fibrinogen 455G>A gene polymorphism 
among RPL patients and controls showed that the difference was not significant ( P-
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Table 4-4: Alleles frequency of β–fibrinogen 455 G>A polymorphism among RPL 



















4.2.3. Hardy-Weinberg equilibrium in β–fibrinogen 455G>A gene 
polymorphism 
Frequency of major allele G (p) = 62x2 + 31x1/97x2 = 0.799 
Frequency of minor allele A (q) = 4x2 + 31x1/97x2 = 0.201 
p + q = 1 
(p + q)
2
 = 1 
P
2
 + 2pq + q
2
 
Expected genotype frequencies: 
Genotype GG: p
2
 x97 = (0.799)
2
 X 97 = 61.93 
Genotype GA: 2pq x97 = 2X0.799X 0.201X 97 = 31.16 
Genotype AA: q
2
 x97 = (0.201)
2
X 97 = 3.92 
Table (4-5) illustrates the observed and expected genotype frequencies of β-fibrinogen 
455G>A gene polymorphism in control women with P-value = 0.9597. This shows that 
there is no significant deviation from Hardy-Weinberg equilibrium, so the distribution 
of β–fibrinogen 455G>A genotypes are in Hardy-Weinberg equilibrium. 
Table 4-5: Observed and expected genotype frequencies of β-fibrinogen 455G>A 
polymorphism 
 GG GA AA 
Observed genotype 62 31 4 
Expected genotype 61.93 31.16 3.92 
P- value = 0.9597                      Chi square: X
2
 = 52.1031 
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4.2.4. Distribution of β-fibrinogen 455G>A gene polymorphism in the study 
population under recessive model 
Table (4-6) illustrates the frequencies, odd ratio and P-value of the β–fibrinogen 
455G>A gene polymorphism among RPL and control subjects. The frequency of the 
wild type G allele carrier represented by (GG +GA) genotypes was 96.1% in RPL 
patient and 95.9% in controls, while the frequency of polymorphic AA genotype was 
3.9% in RPL patients and 4.1% in controls. The statistical analysis showed that there is 
no significant difference between the two groups (P-value = 0.9422).   
Table 4-6: The frequencies, odds ratio and P-value of the β–fibrinogen 455G>A 
gene polymorphism among RPL and control subjects under recessive model 
Genotype Patient (102) Control (97) OR 95% CI P-value 
GG + GA 98  (96.1%) 93  (95.9%) 
1.0538 0.2561 to 4.3364 0.9422 
AA 4  (3.9%) 4  (4.1%) 
4.2.5. Distribution of β–fibrinogen 455G>A gene polymorphism in the study 
population under dominant model 
Table (4-7) illustrates the frequencies, odds ratio and P-value of the β–fibrinogen 
455G>A gene polymorphism among RPL and control subjects. The frequency of the 
wild type (GG) genotype was 68.6% in RPL patients and 63.9% in controls, while the 
frequency of polymorphic A allele carrier represented by (GA+AA) genotypes was 
31.4% in RPL patients and 36.1% in controls. The statistical analysis showed that there 
is no significant difference between the two groups (P-value = 0.4825).   
Table 4-7: The frequencies, odds ratio and P-value of the β–fibrinogen 455G>A 
gene polymorphism among RPL and control subjects under dominant model 
Genotype Patient Control OR 95% CI P value 
GG 70 (68.6%) 62 (63.9%) 
1.2349 0.6854 to 2.2250 P = 0.4825 
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4.3. HPA-1 a/b gene polymorphism 
4.3.1.  Genotypes frequency of the HPA-1 a/b polymorphism among RPL 
patients and controls 
Table (4 -8) and (Fig. 4-5) illustrate the frequencies of genotypes of  the HPA-1 a/b  
gene polymorphism among RPL patients. The frequency of the wild type aa was 68.6%, 
the frequency of the heterozygote ab was 29.4% while, the frequency of the 
homozygous polymorphic allele bb was 2.0 %.    
Table 4-8: Genotypes frequency of HPA-1 a/b polymorphism among RPL patients 
Genotype Frequency Percent % 
aa 70 68.6 
ab 30 29.4 
bb 2 2.0 
Total 102 100.0 
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Table (4 -9) and  (Fig. 4-6) illustrate the frequency of HPA-1 a/b genotypes among 
control women. The frequency of the wild type aa was 63.9 %, the frequency of the 
heterozygote ab was 34.0 % and that of the homozygous bb was 2.1 %.    
Table 4-9: Genotypes frequency of HPA-1 a/b polymorphism among controls 
Genotype Frequency Percent 
aa 62 63.9 
ab 33 34.0 
bb 2 2.1 
Total 97 100.0 
 
 
Fig 4-6: Genotypes frequency of HPA-1 a/b polymorphism among controls 
Table (4-10) illustrates genotypes frequency, odds ratio, 95% confidence intervals and 
P-value of the HPA-1 a/b gene polymorphism among RPL patients and controls. The 
statistical analysis of the frequencies of HPA-1 a/b gene polymorphism among RPL 
patients and controls showed that the difference was not significant in the three 
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Table 4-10: Genotypes frequency of the HPA-1 a/b gene polymorphism among 
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4.3.2.  Allele Frequency of the HPA-1 a/b polymorphism among RPL 
patients and controls 
Table (4-11) illustrates allele frequency, odds ratio, 95% confidence intervals and P 
value  of HPA-1 a/b polymorphism among RPL patients and controls. The statistical 
analysis of allele frequency of HPA-1 a/b gene polymorphism among RPL patients and 
controls showed that the difference was not significant ( P-value = 0.5312) between the 
two groups. 
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4.3.3. Hardy-Weinberg equilibrium in HPA-1 a/b gene polymorphism 
Frequency of major allele a  (p) = 62x2 + 33x1/97x2 = 0.81 
Frequency of minor allele b (q) = 2x2 + 33x1/97x2 = 0.19 
p + q = 1 
(p + q)
2
 = 1 
P
2
 + 2pq + q
2
 
Expected genotype frequencies: 
Genotype aa: p2 x97 = (0.81)
2
 X 97 =  63.64 
Genotype ab: 2pq x97 =( 2 X 0.81 X 0.19) X 97 = 29.86 
Genotype bb: q2 x97 = (0.19)
2
 X 97 = 3.50 
Table (4-12) illustrates the observed and expected genotype frequencies of HPA-1 a/b 
gene polymorphism in control women with P-value = 0.3147. This shows that there is 
no significant deviation from Hardy-Weinberg equilibrium, so the distribution of HPA-
1 a/b genotypes in controls are in Hardy-Weinberg equilibrium. 
Table 4-12: Observed and expected genotype frequency of HPA-1 a/b gene 
polymorphism in control women 
 aa ab bb 
Observed genotype 62 33 2 
Expected genotype 63.64 29.86 3.50 
P- value = 0.3147          Chi square: X
2
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4.3.4. Distribution of HPA-1 a/b gene polymorphism in the study population 
under recessive model 
Table (4-13) illustrates the frequencies, odds ratio and P-value of the HPA-1 a/b gene 
polymorphism among RPL and control subjects. The frequency of the wild type (a) 
allele carriers represented by (aa + ab) genotypes was 98 % in RPL patients and 97.9% 
in controls, while the frequency of the minor polymorphic bb genotype was 2 % in RPL 
patients and 2.1% in controls. The statistical analysis showed that there is no significant 
difference between the two groups (P-value = 0.9595).  
Table 4-13: The frequencies, odd ratio and P-value of the HPA-1 a/b gene 
polymorphism among RPL and control subjects under recessive model 
Genotype Patient Control OR 95% CI P value 
aa + ab 100 (98 %) 95 (97.9 %) 
1.0526 1.453 to 7.6240 0.9595 
bb 2 (2%) 2 (2.1%) 
4.3.5. Distribution of HPA-1 a/b gene polymorphism in the study population 
under dominant model 
Table (4-14) illustrates the frequencies, odds ratio and P-value of the HPA-1 a/b gene 
polymorphism among RPL and control subjects. The frequency of the wild type (aa) 
genotype was 68.6% in RPL patients and 63.9% in controls, while the frequency of 
polymorphic b allele carriers represented by (bb +ab) genotype was 31.4% in RPL 
patients and 36.1% in controls. The statistical analysis showed that there is no 
significant difference between the two groups (P-value = 0.4825).   
Table 4-14: The frequencies, odds ratio and P-value of the HPA-1 a/b gene 
polymorphism among RPL and control subjects under dominant model 
Genotype Patient Control OR 95% CI P value 
aa 70 (68.6%) 62 (63.9%) 
1.2349 0.6854 to 2.2250 0.4825 
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4.4. β–fibrinogen 455G>A gene polymorphism, HPA-1 a/b gene 
polymorphism among patients and controls  
Table (4-15) illustrates the frequencies, odds ratio and P-value of 455 G-A / HPA.1a/b 
cross tabulated among RPL patients and controls investigated in this study. The frequency of  
(GG/aa) genotype was 47% in RPL patients and 40.2% in controls, the difference between the 
two groups was not significant (P-value = 0.3304). There is no significant difference in 
frequencies of all genotypes in the table between the two groups. Genotype (AA/bb) was not 
found in the study population. Genotype (GA/bb) was not found in control sample. 
Table 4-15: The frequencies, odd ratio and P-value of 455 G-A / HPA.1a/b cross 
tabulation among RPL patient and control 
455 G-A / HPA.1a/b 
sample 




































































Chapter (5)                        Discussion 
Recurrent pregnancy loss (RPL) is an important clinical and stressful problem that 
has been studied tremendously but the causes and treatment have not been fully 
resolved (Makino et al., 2004). RPL affects about 1-5% of women who conceive (Su et 
al., 2011) and accounts for about 20% of clinically recognized pregnancy losses 
(Suryanarayana et al., 2006). Despite extensive researches to explain the causative 
effects of RPL, about 50%-60% of RPLs are still idiopathic. A normal pregnancy is 
dependent on adequate placental circulation and fetal vasculature. The development of a 
normal functioning vascular network requires complicated cooperation between 
different cell types and various growth factors in the processes of implantation, 
placentation and embryo development (Su et al., 2011). In pregnancy, there is an 
increase in fibrinogen, von Willebrand factor, and clotting factors II, VII, VIII, IX, and 
X. (Brenner et al., 2006; Barbour et al., 1997) There is a decrease in physiologic 
anticoagulants manifested by a decrease in protein S (PS)  and an increase in protein C 
(PC) resistance. There are decreases in fibrinolytic activity, increased venous stasis, and 
vascular injury associated with delivery. Pregnancy is associated with increased clotting 
potential, decreased anticoagulant activity, and decreased fibrinolyis. (Creasy et al., 
2009). These events require coordination and regulation of expression of many genes 
simultaneously. There is still controversy about the functional significance of different 
genetic factors in reproduction. Genetic studies may provide clues for the evaluation of 
the importance of different, fibrinolytic, thrombophilic, immunogenic and angiogenic 
molecules in RPL. Although there are increasing prospective studies with sufficient 
power related to the association between various thrombophilia and RPL, controversy 
still remains regarding screening for thrombophilia in women with RPL. Routine 
screening is not cost-effective and justified. On the other hand, clinicians need 
guidelines for screening. Guidelines regarding this issue should be prepared according 
to the frequency of thrombophilic defects in the same population. This study was 
designed to investigate the association between spontaneous recurrent pregnancy loss 
(RPL) and the common polymorphisms in β-fibrinogen (-455 G>A; "rs1800790") and 
56 
 
Chapter (5)                        Discussion 
Integrin beta-3 a/b (L33P; " rs5918") genes among Palestinian women residing in Gaza 
Strip. 
5.1. The study population 
Definitions of RPL have varied between studies. Some
 
previous studies have defined 
RPL as three or more miscarriages
 
before 20 weeks of gestation (Minardi et al., 1999; 
Carp et
 
al., 2001), whereas others have not (Kutteh et al., 1999). This study
 
opted for 
defining RPL as three or more miscarriages
 
before 20 weeks of gestation in order to 
provide comparable
 
data. It has to be kept in mind, however, that miscarriages
 
in early 
pregnancy might be etiologically different than those
 
occurring early in the second 
trimester.
 
The results obtained in the majority of studies describing genetic 
polymorphisms in RPL are conflicting. Many of the reported associations have not been 
reproduced in later studies. This is partly due to the fact that the associations may vary 
in different ethnic populations (reflecting the multifunctional nature of RPL risk) and 
they may be biased because of small sample sizes. This also may be true in the present 
study. One reason for a small sample size is that RPL is relatively uncommon, and may 
be as low as 1% in women.  
Collaboration between research groups may resolve the problem of small sample sizes, 
but comparison of results from different ethnic backgrounds has its weaknesses. The 
study and control populations should remain as homogenous as possible. Ethnic 
variation and genetic admixture need to be considered
 
in any evaluation of the genetic 
background of RPL (Hartl and
 
Clark, 1992). The Palestinians residing in Gaza Strip 
may constitute an ideal population for such studies, our population is a small and has a 
high frequency of consanguineous marriage. Thus, we expect that our population gene 
pool is homogenous. 
The Palestinian population that was the subject of this investigation, offered another 
advantage, alcohol or drug use were irrelevant in the context of Palestinian women in  
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the reproductive age. Smoking role in RPL is not yet clearly defined, and due to 
extremely low rate of smoking among young Palestinian women which are the usual 
confounding, environmental factors in such types of studies.  
5.2. Association between β-fibrinogen (-455 G>A; "rs1800790") gene 
polymorphisms and RPL 
The distribution β–fibrinogen 455G>A genotypes in the control group is  in Hardy-
Weinberg equilibrium as no significant deviation  (P- value = 0.9597) was recorded 
between observed and expected genotypes. 
The GG genotype was less prevalent in the control women (63.9%) as compared to the 
RPL patients (68.6%), though the difference was not significant (P-value = 0.4825), 
while the GA genotype and AA genotype were more frequent in the control women 
(32.0%, 4.1% respectively) relative to RPL patients (27.5%, 3.9% respectively), but the 
difference was not significant (P-value = 0.4868, 0.9422 respectively). 
Results of this study showed that the β-fibrinogen -455G>A polymorphism was not 
significantly different between RPL patients and the controls (all P-values > 0.05). This 
non-significant relation was observed under both dominant and recessive models.  
This study showed that the allele frequencies of -455G>A also are not significantly 
different between RPL patients and controls (P-value = 0.5314). The frequency of 
polymorphic A allele was less prevalent in RPL patients (17.6% ) than in controls 
(20.1%) and the wild type G allele was more prevalent in RPL patients (82.4%) than in 
controls (79.9%). It can be inferred that the documented RPL risk factor, -455G>A  is 
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Lack of association between RPL and β-fibrinogen -455 G>A polymorphism 
observed in this study is in agreement with the findings reported by (Pihusch et al., 
2001; Camilleri et al., 2004; Goodman et al., 2006; Coulam et al., 2006; Yenicesu et al., 
2010 and Ozdemir et al., 2012) 
Coulam et al., 2006 studied β-fibrinogen -455 G>A polymorphism in 150 women 
and found no differences in the frequency of 455G>A polymorphism between RPL 
women and controls. Coulam et al., concluded that the inherited thrombophilias are 
associated with recurrent miscarriage and that this association is manifested by the total 
number of mutations rather than specific genes involved.  
Pihusch et al., 2001 studied β-fibrinogen -455 G>A polymorphism in 102 RPL 
patients compared with 128 control fertile women and observed no difference in 
prevalence between the two groups. Yenicesu et al., 2010 studied 455G>A in 272 
women compared with 56 controls women  and showed that there was no association 
between RPL and this polymorphism. 
Goodman et al., 2006, studied 455G>A and other polymorphic genes in 550 women 
and they showed that there was no meaningful association between RPL and 455G>A 
gene polymorphism when investigated individually. 
Coulam et al., 2006; Pihusch et al., 2001 and Goodman et al., 2006 concluded that 
while β-fibrinogen -455G/A polymorphism is a risk factor for thrombosis, this mutation 
by itself has not been shown to be associated with recurrent miscarriage. 
Camilleri et al., 2004 showed that no significant differences were observed in the -
455A allelic frequencies of the patient and normal control group. 
Contrary to our findings, Torabi et al., 2012, showed that there was association 
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5.3. Association between Integrin beta-3 a/b (L33P; " rs5918") gene 
polymorphism and RPL 
Analysis of genotyping results of the control group showed that there is no 
significant deviation from Hardy-Weinberg equilibrium (P- value = 0.3147), so the 
distribution of HPA-1a/b genotypes are in Hardy-Weinberg equilibrium. 
The "aa" genotype was less prevalent in control women (63.9%) as compared to RPL 
patients (68.6%), though the difference was not significant (P- value = 0.4825), while 
the "ab" and "bb" genotypes were more frequent in control women (34.0%, 2.1% 
respectively) than in RPL patients (29.4%, 2% respectively), but without statistical 
significance (P-value = 0.4851, 0.9595 respectively). This non-significant association 
held true under both dominant model and recessive genetic models. These results 
indicate that the genotype HPA-1a/b polymorphism is not significantly associated with 
RPL in our study population. 
Not only the genotypes but also the individual alleles' frequencies of HPA-1a/b did 
not show  significant difference between RPL patients and controls with (P-value = 
0.5312). The frequency of the polymorphic "b" allele was less prevalent in RPL patients 
(16.6%) than in controls (19.0%) and that of the wild type "a" allele was more prevalent 
in RPL patients (83.3%) than in controls (81.0%). It can be inferred that the 
documented RPL risk factor, HPA-1a/b allele, is
 
not associated with RPL.  
Lack of association between RPL and HPA-1a/b polymorphism observed in this 
study is in agreement with the results of Coulam et al., 2006; Pihusch et al., 2001;  and 
Goodman et al., 2006; Torabi et al., 2012; Hohlagschwandtner et al., 2003; Ozdemir et 
al., 2012 ). 
Coulam et al., 2006; Pihusch et al., 2001; Ozdemir et al., 2012 and 
Hohlagschwandtner et al., 2003  had not observed an association between human 
platelet antigen glycoprotein IIb/IIIa and RPL.  
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Goodman et al., 2006, showed that there was no meaningful of association between 
RPL and HPA-1a/b gene polymorphism when investigated individually. 
Torabi et al. (2012) however, showed that the ITGB3 1565T/C (HPA-1 a/b) 
genotype distribution significantly differed between the case and control groups, 
However, the variant genotypes (ab and bb) were more frequent in the control group (p 
<0.001).  Considering the more frequent variant genotypes of ITGB3 1565T ⁄C in the 
control group, it seems to be unrelated to an increased risk for RPL or it may have a 
protective effect against. 
Meanwhile,, results described by Yenicesu et al., (2010) indicated that heterozygous 
mutation of HPA-1a/b polymorphism is significantly associated with RPL. and  
Goncharova et al., (2013) indicated that the "b" allele and the "bb" genotype of the  
ITGB3 gene in Russian women is associated with recurrent miscarriage.  
Discrepancy between results of genetic association studies like those encountered 
here could be due to many reasons including population genetic variation (background) 
unrelated to the alleles, presence of nucleotide polymorphism somewhere else  in the 
examined allele e.g., in the untranslated or intronic regions, epigenetic alterations and 
linkage disequilibrium to other sequence variants in the vicinity of the studied loci.  
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5.4. Allele frequency of the -455G>A and HPA-1a/b polymorphism  
The calculated relative frequency for the 455G>A polymorphism in this study (455 G/A 
0.799 / 0.201) is different from that reported in other ethnic groups (Table 5-1). 
Notably, the Palestinians allele frequency is different from that of Egyptians. 
Table 5-1: Allele frequency of the FGB -455 G/A polymorphism among different 





Korean  0.83 0.17 267 Lee et al., 2008  
Greek 0.83 0.17 121 Xenophontos et al., 2002  
Saudi Arabia 0.825 0.175 200 El-Tarras et al.,2012 
Finland 0.82 0.18 249 Martiskainen et al., 2011  
Chinese Han population 0.8 0.2 503 Xiang-feng et al., 2008  
Palestinian  0.799 0.201 97 Present study  
South Asians of United Kingdom  0.79 0.21 100 Kain et al., 2002  
Lebanese  0.77 0.23 160 Shammaa et al., 2008  
Chinese 0.75 0.245 402 Liu et al., 2002  
Whites of United Kingdom  0.745 0.235 100 Kain et al., 2002  
Egypt 0.5 0.5 17 El-Tarras et al.,2012 
 
The calculated relative frequency for the HPA-1a/b polymorphism in this study is 
comparable to that found in many other populations (Table 5-2). Interestingly, our 
allele frequencies are identical to those reported for the Lebanese and Greece 
populations. This in fact increases the validity of our data, since Palestinian, Greek and 
Lebanese populations have resided together in the Eastern Mediterranean basin for 
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Table 5-2: Allele frequencies of HPA-1a and -1b in different populations 
(Adopted from Salem et al., 2009; Tan et al., 2012) 
Population 
Allele Frequency  
N Reference 
a b 
Berber Moroccan 0.748 0.252 110 Ferrer et al., 2002 
Tunisian 0.750 0.250 90 Mojaat et al., 1999 
Bahraini 0.760 0.240 194 Al-Subaie et al., 2007 
Egyptian 0.767 0.233 206 Salem et al., 2009 
Lebanese 0.810 0.190 205 Sabbagh et al., 2007 
Palestinian  0.810 0.190 97 Present study 
Greek 0.810 0.190 55 Chiras et al., 2009 
Danish 0.831 0.169 557 Steffensen et al., 1996 
French 0.848 0.152 800 Merieux et al., 1997 
Spanish 0.851 0.149 500 Muniz-Diaz et al., 1993 
Austrian 0.852 0.148 911 Holensteiner et al., 1995 
Polish 0.874 0.126 135 Drzewek et al., 1998 
Caucasian-American 0.890 0.110 100 Kim et al., 1995 
African-American 0.920 0.080 100 Kim et al., 1995 
Korean 0.988 0.012 200 Seo et al., 1998 
Japanese 0.998 0.002 331 Tanaka et al., 1996 
Amazon Indian 1.000 0.000 95 Chiba et al., 2000 
 
In conclusion, results of the present study revealed that there is no appreciable 
association between the investigated β–fibrinogen (-455 G>A) or  Integrin beta-3 
(L33P) common polymorphisms and the occurrence of first trimester RPL. Thus, these 
two polymorphisms do not constitute an important risk factor for RPL in our 
population. Future work should be directed towards investigating the relation between 
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6.1. Conclusion 
The present study focused on the polymorphism of β-fibrinogen (-455 G>A; 
"rs1800790") and Integrin beta-3 a/b (L33P; " rs5918") genes in 102 Palestinian women 
in Gaza Strip suffering from RPL. The results of the study can be summarized as 
follows: 
 The study showed that there is no significant association between the  β-
fibrinogen -455 G>A polymorphism and RPL. 
 
 No significant association was observed between Integrin beta3 (L33P) 
polymorphism and RPL. 
 
 The distribution of β-fibrinogen -455 G>A and Integrin beta-3 a/b 
polymorphisms are both in Hardy –Weinberg equilibrium. 
 
 The allele frequency of HPA-1 a/b polymorphism in this study (0.81/0.19) is 
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6.2. Recommendations 
The study recommends: 
1. Before ordering genetic testing for patients, it is essential to thoroughly confirm 
the association between the test and the disease. Especially with respect to 
gene(s) polymorphism(s) and RPL. Studies in other people and ethnic groups 
may not be applicable to the Gaza strip population.  
 
2. Performing larger studies and perhaps meta-analyses in order to investigate the 
association between β-fibrinogen (-455 G>A) and Integrin beta-3 a/b (L33P) 
polymorphisms and  RPL among Palestinian women. 
 
3. Performing larger studies to calculate the frequency of HPA-1b and β-fibrinogen 
A alleles in Palestinian population. 
 
4. Performing further studies to investigate the relation between other 
polymorphisms in these two and other genes related to thrombophilia and RPL. 
 
5. Performing further studies to investigate the impact of several mutations in a 
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